BioAscent’s Chief Scientific Officer, Dr Phil Jones, joined industry colleagues to discuss the integrated drug discovery offering at the recent “Collaboration and Outsourcing in Drug Discovery” Workshop at the 2021 Bio2Business BOS Virtual event.
BOS (Biotech Outsourcing Strategies) is an established outsourcing-focused conference and exhibition for the international pharmaceutical industry. The event scope is focused on discovery outsourcing and CMC outsourcing for both small molecules and biologics (primarily development stage).
In his presentation, Phil Jones discussed BioAscent’s integrated drug discovery model for collaboration and outsourcing, focusing on the capabilities and logistics expertise this type of model provides.
As Phil explains in his presentation: "I don’t think the integrated drug discovery approach needs much justification as it has proven to be very successful here at BioAscent. The approach is driven by scientific quality, expertise, experience and particularly communication in a collaborative environment."